The purpose of this study is to evaluate the efficacy and safety of allogeneic γδ T cells in patients with MRD-positive AML after allo-HSCT.
Patients should sign informed consent form voluntarily before the trail and comply with the requirements of this study.
Age≥18 years old, gender unlimited.
All the subjects met the 2016 WHO classification and were diagnosed with AML via MICM (Morphology,Immunophenotyping, Cytogenetics, and Molecular genetics).
AML patients receiving allo-HSCT.
Post-transplant relapse or extramedullary disease: AML patients post-allo-HSCT with ≥5% blasts in peripheral blood or bone marrow (excluding causes such as bone marrow regeneration after consolidation chemotherapy) or extramedullary leukemia infiltration.
Active GVHD: Subjects with active GVHD within 30 days before screening.
Active infections: HBV, HCV, HIV, syphilis (TP), active CMV, or EBV infection.
Neurological disorders: active autoimmune or inflammatory neurological diseases, clinically significant active cerebrovascular disease.